An Observational, Prospective Post-Marketing Surveillance Program to Evaluate the Safety Profile of Intravitreal Ozurdex® in the Treatment of Visual Impairment Due to Diabetic Macular Edema by Actively Identifying and Evaluating the Occurrence of Adverse Events and Serious Adverse Events Information

Trial Profile

An Observational, Prospective Post-Marketing Surveillance Program to Evaluate the Safety Profile of Intravitreal Ozurdex® in the Treatment of Visual Impairment Due to Diabetic Macular Edema by Actively Identifying and Evaluating the Occurrence of Adverse Events and Serious Adverse Events Information

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 May 2017

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors Allergan
  • Most Recent Events

    • 30 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top